

## WEST Search History

DATE: Friday, February 18, 2000

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L12	L3 and L6	54	L12
L11	L3 and L5	108	L11
L10	L2 and L6	0	L10
L9	L2 and L5	0	L9
L8	L1 and L6	21	L8
L7	L1 and L5	66	L7
L6	ribozym\$3	9962	L6
L5	antisens\$3	28519	L5
L4	1, 25 dihydroxyvitamin D3 receptor	0	L4
L3	vitamin D receptor	596	L3
L2	NR1H1	1	L2
L1	VDR	887	L1

END OF SEARCH HISTORY



ACCESSION NUMBER: 2002:304662 BIOSIS  
DOCUMENT NUMBER: PREV2002:304662  
TITLE: Non-genomic stimulation of tyrosine phosphorylation cascades by 1,25(OH)<sub>2</sub>D<sub>3</sub> by VDR-dependent and -independent mechanisms in muscle cells.  
AUTHOR(S): Holland, Richard L.; De Holland, Ann Kusan; Palmarini, Claudio; Morelli, Susana; Santillan, Graciela; Tappin, William; Tappin, Daniela; Balci, Celine  
CORPORATE AUTHOR: Universidad de Buenos Aires, Facultad de Medicina, Universidad Nacional de La Plata, Facultad de Medicina, Buenos Aires, Argentina  
JOURNAL: Steroids, May, 2002, Vol. 57, No. 5, pp. 477-481.  
http://www.elsevier.com/locate/steroids print.  
ISSN: 0039-128X.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
AB: Studies with different cell types have shown that modulation of various of the fast as well as long-term responses to 1,25(OH)<sub>2</sub>D<sub>3</sub> depends on the activation of tyrosine kinase pathways. Recent investigations of our laboratory have demonstrated that 1,25(OH)<sub>2</sub>D<sub>3</sub> rapidly stimulates in muscle cells tyrosine phosphorylation of PLC-gamma and the growth-related proteins MAPK and c-myc. We have now obtained evidence using antisense technology indicating that VDR-dependent activation of Src mediates the fast stimulation of tyrosine phosphorylation of c-myc elicited by the hormone. This non-genomic action of 1,25(OH)<sub>2</sub>D<sub>3</sub> requires tyrosine phosphorylation of the VDR. Immunoprecipitation under native conditions coupled to Western blot analysis revealed 1,25(OH)<sub>2</sub>D<sub>3</sub>-dependent formation of complexes between Src and the VDR and c-myc. However, the activation of MAPK by the hormone was only partially mediated by the VDR and required in addition increased PKC and intracellular Ca<sup>2+</sup>. Following its phosphorylation, MAPK translocates into the nucleus where it regulates c-myc transcription. Altogether these results indicate that tyrosine phosphorylation plays a role in the stimulation of muscle cell growth by 1,25(OH)<sub>2</sub>D<sub>3</sub>. Data were also obtained involving tyrosine kinases and the VDR in hormone regulation of the Ca<sup>2+</sup> messenger system by mediating the stimulation of store-operated calcium (SOC; TRP) channels. Congruent with this action, 1,25(OH)<sub>2</sub>D<sub>3</sub> induces a rapid translocation of the VDR to the plasma cell membrane which can be blocked by tyrosine kinase inhibitors. Of mechanistic relevance, an association between the VDR and TRP proteins with the participation of the scaffold protein INAD was shown.

ACCESSION NUMBER: 2002:444046 BIOSIS  
DOCUMENT NUMBER: PREV2002:444046  
TITLE: Alteration of cellular phosphorylation state affects vitamin D receptor-mediated CYP24 mRNA induction in Fetal cells.  
AUTHOR(S): Kim, Hyeonmi; Yehmami, Yoon; Ancho, Eusebio  
CORPORATE AUTHOR: Department of Clinical Pharmacology, Kitano Pharmaceutical University, 2-1-1 Inaba-cho, Inaba, Tokyo, 107-8585, Japan  
JOURNAL: Biochemical and Biophysical Research Communications, August 7, 2002, Vol. 296, No. 1, pp. 161-166.  
http://www.sciencedirect.com/locate/bbrc print.  
ISSN: 0006-291X.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
AB: Expression of cytochrome P450 CYP24 is induced by 1,25-dihydroxyvitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>) in fetal cells. However, since a

typical vitamin D response element was not found and in the 3'-flanking region of the CYP3A4 gene, the mechanism of 1,25(OH)<sub>2</sub>D<sub>3</sub>-induced CYP3A4 mRNA expression is poorly understood. In the present study, we demonstrated that vitamin D receptor **VDR** is a critical factor for the induction using the **antisense** oligonucleotide technique. In addition, we found that treatment of Caco-2 cells with the protein kinase C (PKC) inhibitors, staurosporine and GF109203X, and the tyrosine kinase inhibitor, genistein, but not with the protein kinase A inhibitor, H-89, suppressed CYP3A4 mRNA induction by 1,25(OH)<sub>2</sub>D<sub>3</sub>. The depletion of PKC by prolonged treatment with phorbol ester abolished the induction. On the other hand, protein kinase inhibitors used had no effects on the constitutive expression of **VDR** mRNA. Therefore, these observations suggest that 1,25(OH)<sub>2</sub>D<sub>3</sub>-induced CYP3A4 mRNA expression might be involved in phosphorylation events in addition to transcriptional regulation via **VDR**. However, 1,25(OH)<sub>2</sub>D<sub>3</sub> did not rapidly activate PKC in the Caco-2 cells used, while the treatment with staurosporine and GF109203X, but not genistein, decreased basal PKC activity by approx30% of the controls. Taken together, these findings suggest that the change in the phosphorylation state via PKC and tyrosine kinase might, at least in part, mediate 1,25(OH)<sub>2</sub>D<sub>3</sub>-induced CYP3A4 mRNA expression via **VDR**.

1.9 ANSWER 3 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE

ACCESSION NUMBER: 2002:146648 BIOSIS  
DOCUMENT NUMBER: PREV200200146648  
TITLE: The vitamin D receptor mediates rapid changes in muscle protein tyrosine phosphorylation induced by 1,25(OH)<sub>2</sub>D<sub>3</sub>.  
AUTHOR(S): Buitrago, Claudia; Vacques, Guillermo; De Boland, Ana R.; Boland, Ricardo [1]  
CORPORATE SOURCE: (1) Departamento de Biologia, Bioquimica and Farmacia, Universidad Nacional del Sur, San Juan 670, 4000, Bahia Blanca: rboland@criba.edu.ar Argentina  
SOURCE: Biochemical and Biophysical Research Communications, (December 21, 2002) Vol. 289, No. 3, pp. 1154-1156. <http://www.academicpress.com/cbrcr.print>. ISSN: 0006-291X.

DOCUMENT TYPE: Article  
LANGUAGE: English

AB It has been recently shown that the fast non-genomic responses of 1,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> [1,25(OH)<sub>2</sub>D<sub>3</sub>] in skeletal muscle cells involve tyrosine phosphorylation of MAP kinase (ERK1/2), c-Src kinase and the oncoprotein c-myc. In the present work, blockade of vitamin D receptor **VDR** expression [interfered] by preincubation of chick embryonic muscle cells with three different **antisense** oligonucleotides against the **VDR** mRNA (AS-**VDR** ODNs) significantly reduced (-24%) 1,25(OH)<sub>2</sub>D<sub>3</sub> stimulation of c-myc tyrosine phosphorylation and inhibited c-Src tyrosine dephosphorylation implying lack of c-Src activation by the hormone. Co-immunoprecipitation experiments revealed that 1,25(OH)<sub>2</sub>D<sub>3</sub> induces the formation of complexes between c-Src and c-myc, in agreement with the above results and previous studies showing hormone-dependent association between c-Src and tyrosine phosphorylated **VDR** and c-Src mediated c-myc tyrosine phosphorylation. MAPK tyrosine phosphorylation by 1,25(OH)<sub>2</sub>D<sub>3</sub> was affected to a lesser extent (-35%) by transfection with AS-**VDR** ODNs implying that both **VDR**-dependent and **VDR**-independent signalling mediate hormone stimulation of MAPK. These are the first results providing the evidence on the participation of the **VDR** in a non-genomic 1,25(OH)<sub>2</sub>D<sub>3</sub> signal transduction. Activation of tyrosine phosphorylation provides the immediate molecular mechanism for the regulation of muscle growth.

1.9 ANSWER 4 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE

ACCESSION NUMBER: 2000:247104 BIOSIS  
 DOCUMENT NUMBER: PREVIOUS:247104  
 TITLE: Steroid receptor co-activator-1 mediates 1,25-dihydroxyvitamin D3-stimulated alkaline phosphatase in human osteosarcoma cells.  
 AUTHOR(S): Gill, S. M. J.; Gill, M. H.  
 CORPORATE SOURCE: 1. Department of Medicine, Division of Bone and Mineral Metabolism, Medical University of South Carolina, 174 Ashley Street, Charleston, SC, 29425 USA  
 SOURCE: Calcified Tissue International, May, 2001 Vol. 60, No. 5, pp. 407-411.  
 ISSN: 0939-6460.  
 DOCUMENT TYPE: Article  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English

AB For steroid hormone function to occur, nuclear receptors interact with a series of coactivators including steroid receptor coactivator-1 (SRC-1). The SRC-1 binds the vitamin D receptor (VDR) in the presence of ligand in an activation function 2 (AF-2)-dependent manner. In order to understand the role of this interaction in 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3)-mediated gene expression, the level of SRC-1 expression was altered in MG-63 cells. Previous studies had demonstrated that MG-63 cells express the VDR and that 1,25(OH)2D3 regulates expression of alkaline phosphatase (ALP). Analysis of MG-63 cells demonstrated that SRC-1 is expressed. A full-length cDNA coding for SRC-1 was inserted in **antisense** orientation into an expression vector (anti-SRC-1). The MG-63 cells were transfected with anti-SRC-1 or mock vector and stable transformants were selected. Western blot analysis showed a 50% reduction in SRC-1 protein as compared with mock cells. We determined the effect of normal and reduced SRC-1 expression in MG-63 cells on 1,25(OH)2D3-mediated stimulation of ALP. Whereas 10<sup>-8</sup> M 1,25(OH)2D3 produced a 2.5-fold stimulation of ALP in mock cells expressing normal levels of SRC-1, it did not alter ALP in cells expressing reduced levels of SRC-1. Thus, SRC-1 is required for 1,25(OH)2D3-mediated gene expression of ALP by human MG-63 cells.

19 ANSWER 5 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. UPDATE 8

ACCESSION NUMBER: 2000:50707 BIOSIS  
 DOCUMENT NUMBER: PREVIOUS:50707  
 TITLE: 1alpha,25-dihydroxyvitamin D3-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex.  
 AUTHOR(S): Hnana, Zakaria; Nandan, Devki; Sly, Laura; Knudson, Keith L.; Herrera-Velaz, Patricia; Reiner, Neil E. [1]  
 CORPORATE SOURCE: [1] Division of Infectious Diseases, University of British Columbia, 2783 Heather St., Rm. 4323, Vancouver, BC Canada  
 SOURCE: Journal of Experimental Medicine, Dec. 6, 2000 Vol. 192, No. 12, pp. 1533-1544.  
 ISSN: 0021-8758.  
 DOCUMENT TYPE: Article  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English

AB 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) promotes the maturation of myeloid cells and surface expression of CD14 and CD11b, markers of cell differentiation in response to 1,25(OH)2D3. To examine how these responses are regulated, THP-1 cells were grown in serum-free medium and treated with 1,25(OH)2D3. This was associated with rapid and transient increases in phosphatidylinositol 3-kinase (PI 3-kinase) activity. Furthermore, induction of CD14 expression in response to 1,25(OH)2D3 was dependent on the PI 3-kinase inhibitors LY294002 and wortmannin; **antisense** oligonucleotides to cDNA for the p110 catalytic subunit of PI 3-kinase; and on a dominant-negative mutant of PI 3-kinase. In THP-1 cells, inhibition of CD14 expression by 1,25(OH)2D3 was also associated by LY294002 and

estradiol. Similarly, 17 $\beta$ -E and estradiol inhibited IL-1-induced expression of both M14 and M18 in peripheral blood monocytes. In contrast to M14 and M18, hormone-induced expression of the P84 inhibitor p84 in THP-1 cells was unaffected by either estradiol or 17 $\beta$ -E. These findings suggest that PI 3-kinase selectively regulates IL-1-induced monocyte differentiation, independent of any effects on p84. Pretreatment of THP-1 cells with **antisense** oligonucleotides to the vitamin D receptor **VDR** mRNA abrogated both activation of PI 3-kinase in response to IL-1 and hormone-induced M14 expression. Moreover, both Western blots and in vitro kinase assays carried out on immunoprecipitates of the **VDR** showed that IL-1 treatment brought about formation of a complex containing both PI 3-kinase and the **VDR**. These findings reveal a novel, nongenomic mechanism of hormone action regulating monocyte differentiation, in which vitamin D $_3$  activates a **VDR**- and PI 3-kinase-dependent signaling pathway.

12 ANSWER 6 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INDIVIDUAL

ACCESSION NUMBER: 1999:4412 BIOSIS  
DOCUMENT NUMBER: 1999:4412  
TITLE: Characterization of an enhancer required for 1,25-dihydroxyvitamin D $_3$ -dependent transactivation of the rat osteocalcin gene.  
AUTHOR(S): Sneddon, W. Bruce; Demay, Marie B. (1)  
CORPORATE SOURCE: (1) Endocrine Unit, Wellman 8-1, Massachusetts General Hospital, Boston, MA, 02114 USA  
SOURCE: Journal of Cellular Biochemistry, (June 1, 1999) Vol. 73, No. 3, pp. 401-407.  
ISSN: 0730-2312.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
SUMMARY LANGUAGE: English

AB The sequences in the rat osteocalcin gene that lie 3' to the vitamin D response element (VDRE) contain a GGTTTGG motif (-420 to -414) that is essential for transcriptional activation of osteocalcin-CAT (OC-CAT) fusion genes by 1,25(OH) $_2$ D $_3$ . A second copy of this motif, present on the **antisense** strand is unable to compete for nuclear protein binding to the VDRE-associated motif, suggesting that the core element extends beyond the GGTTTGG motif. In order to examine the base requirements for both function and nuclear protein interactions with the VDRE-associated GGTTTGG enhancer motif, deletion and substitution of flanking sequences was performed in the context of both the native osteocalcin promoter and a heterologous viral promoter. These data demonstrate that the base requirements for protein-DNA interactions and transactivation are located between -430 and -414. The position of the element with respect to the VDRE is flexible and insertion of additional copies either 3' or 5' to the VDRE further enhances transactivation, both in the context of the native osteocalcin promoter and a heterologous viral promoter. These data demonstrate that **VDR**-dependent transactivation of the rat osteocalcin gene requires not only the VDRE (-486 to -442) but also sequences between -430 and -414. The protein(s) that interacts with these sequences is capable of enhancing transcription in both a position and orientation-independent fashion.

12 ANSWER 7 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INDIVIDUAL

ACCESSION NUMBER: 1999:4410 BIOSIS  
DOCUMENT NUMBER: 1999:4410  
TITLE: Isolation and characterization of a novel protein that binds to the 3'-terminal region of the human A1-antitrypsin gene.  
AUTHOR(S): Kikuchi, Akira; Imai, Yumiko; Kato, Chikako; Yamaoka, Shiro; Nakamura, Shigeaki  
CORPORATE SOURCE: (1) Dep. of Molecular Biology, Osaka Univ. School of Medicine,  
2-2 Yamadaoka, Suita, Osaka 565, Japan

Keiyakindai, Okada City, Saitama 351-12, Japan.  
SOURCE: Journal of Biological Chemistry, June 12, 1997, Vol. 272,  
No. 24, pp. 14733-14741.  
ISSN: 0021-9259.

DOCUMENT TYPE: Article  
LANGUAGE: English

AB The present study demonstrates that  $1,25\text{-}(\text{OH})_2\text{D}_3$  synergistically enhances TGF- $\beta$ -induced AP-1 activity in rat osteoblastic MC3T3-E1 cells via the vitamin D receptor (VDR).  $1,25\text{-}(\text{OH})_2\text{D}_3$  synergistically stimulated TGF- $\beta$ -induced expression of the c-jun gene in the cells transfected with the c-jun gene. We initially showed by a gel mobility shift assay that  $1,25\text{-}(\text{OH})_2\text{D}_3$  synergism of TGF- $\beta$ -induced AP-1 binding to the 12-O-tetradecanoylphorbol-13-acetate response element (TRE).  $1,25\text{-}(\text{OH})_2\text{D}_3$  markedly stimulated the transient activity of TGF- $\beta$ -induced AP-1 in the cells transfected with a TRE-chloramphenicol acetyltransferase (CAT) reporter gene. Also, a synergistic increase in TGF- $\beta$ -induced CAT activity was observed in the cells cotransfected with an expression vector encoding vitamin D receptor (VDR) and the reporter gene. However, the synergistic CAT activity was inhibited by pretreatment with VDR antisense oligonucleotides. In addition, in a Northern blot assay, we observed  $1,25\text{-}(\text{OH})_2\text{D}_3$  synergism of TGF- $\beta$ -induced expression of the c-jun gene in the cells transfected with the VDR expression vector and also found that the synergistic action was clearly blocked by VDR antisense oligonucleotide pretreatment. The present study strongly suggests a novel positive regulation by  $1,25\text{-}(\text{OH})_2\text{D}_3$  of TGF- $\beta$ -induced AP-1 activity in osteoblasts via "genomic action."

12 ANSWER # OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INCORPORATE  
11

ACCESSION NUMBERS: 1996:116901 BIOSIS  
COMMENT NUMBER: IREV1996:16660  
TITLE: A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with E1 antigen to mediate negative gene regulation by vitamin D.

AUTHOR(S): Nishishita, Toshihide; Okanaki, Tomoki [1]; Ishikawa, Toshio; Igarashi, Tetsuya; Hata, Keishi; Ogata, Eisuro; Fujita, Toshiro

CORPORATE SOURCE: [1] Endocrine Genet. Hypertension Unit, 4th Dep. Internal Med., Univ. Tokyo Sch. Med., Bunkyo-ku, Tokyo 112, Japan

SOURCE: Journal of Biological Chemistry, May 1, 1997, Vol. 272,  
No. 18, pp. 12611-12617.  
ISSN: 0021-9259.

DOCUMENT TYPE: Article  
LANGUAGE: English

AB We found that the human parathyroid hormone-related peptide (hPTHrP) gene contained a DNA element (NTPPHrP) homologous to a negative vitamin D response element in the human parathyroid hormone gene. It bound to vitamin D receptor (VDR) in rat osteoblastic MC3T3-E1 cells. VDR binding to this element was confirmed by the electrophoretic mobility shift assay. Intranuclear binding of anti-VDR monoclonal antibody, anti-NTPPHrP antibody, and anti-E1 antigen antibody by specifically supershifted the NTPPHrP binding activity to NTPPHrP. In electrophoretic mobility shift assay, we found anti-E1 antigen antibody specifically supershifted the NTPPHrP binding activity to NTPPHrP. Also, the NTPPHrP-bound oligonucleotide plasmid protein vitamin D-dependent inhibition of the reporter activity in MC3T3-E1 cells, which was markedly markedly by the introduction of the E1 antigen expression vector in the antisense orientation. In the other hand, such a procedure did not perturb the vitamin D response

differentiated and stimulated by vitamin D. These results indicate that **ANFELITHIS** interacts with **VDR** driven in addition to **VDR** to enhance gene expression by vitamin D.

12 ANSWER 2 OF 13 BIOSIS COPYRIGHT 1996 BIOLOGICAL ABSTRACTS INC.DUPLICATE  
13

ACCESSION NUMBER: 1996:01016 BIOSIS  
DOCUMENT NUMBER: EREV199601016-4  
TITLE: **Antisense** inhibition of vitamin D receptor expression induces apoptosis in myeloblasts [Enl, Enl, Hewison, Martin J.; Dackiwski, Michael; Yaman, Chilly; Farikner, Lee; Cickorill, Elena L.; Brickell, Paul M.; O'Riordan, Jeffrey L. H.; Kohn, David P.  
AUTHOR(S):  
CORPORATE SOURCE: 11 Leg. Medicine, Univ. Birmingham, Queen Elizabeth Bldg., Edgbaston, Birmingham B15 2TH UK  
SOURCE: Journal of Immunology, 1996, Vol. 156, No. 11, pp. 4341-4411.  
ISSN: 0022-1767.  
JOURNAL TYPE: Article  
LANGUAGE: English

AB The active vitamin D-3 metabolite 1,25-dihydroxyvitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>) acts as an antiproliferative and differentiating agent for the monoblastoid cell line U937 and as an important immunologic mediator implicated particularly in the function of cells belonging to the monocyte/macrophage lineage. These effects are controlled by the vitamin D receptor (VDR), a member of the steroid hormone receptor family. The objective of this study was to develop U937 transfectants expressing **antisense VDR mRNA**, and to use these to examine the role of 1,25(OH)<sub>2</sub>D<sub>3</sub>-VDR interaction in this lineage. A 2-Kb VDR cDNA insert (including the complete VDR coding region) was cloned in an **antisense** orientation into the EBV episomal vector pMEP4 under the control of an inducible promoter and transfected into U937. The resultant cell line, CH42, was hygromycin resistant, contained VDR cDNA, expressed fewer VDRs than controls, and showed a substantial decrease in antiproliferative response to 1,25(OH)<sub>2</sub>D<sub>3</sub>. However, 1,25(OH)<sub>2</sub>D<sub>3</sub> increased the number of cells expressing macrophage cell surface Ags, including CD14 and CD11b. A subpopulation of smaller cells did not express the differentiation markers after cadmium stimulation. Cell cycle analysis showed shifts in the distribution of cells from G<sub>1</sub> to S phase, which were more pronounced after cadmium treatment. A considerable proportion of cells were outside the cycle and DNA fragmentation confirmed apoptosis. Thus, the functional outcome of the **VDR antisense** transfection suggests that in the myelomonocytic lineage, VDR expression may act as a protective mechanism against programmed cell death.

12 ANSWER 10 OF 13 BIOSIS COPYRIGHT 1996 BIOLOGICAL ABSTRACTS INC.DUPLICATE  
13

ACCESSION NUMBER: 1996:01016 BIOSIS  
DOCUMENT NUMBER: EREV199601016-4  
TITLE: Vitamin D receptor expression is required for growth modulation by 1-alpha,25-dihydroxyvitamin D-3 in the human prostatic carcinoma cell line ALVA-31.  
AUTHOR(S): Hedlund, T. E.; Murray, K. A.; Miller, A. T.;  
CORPORATE SOURCE: 11 Leg. Pathol., Box 840, Univ. Colorado Health Sci. Ctr., 420 E. Ninth Ave., Denver, CO 80202 USA  
SOURCE: Journal of Cellular Biochemistry and Molecular Biology, 1996, Vol. 61, No. 2, pp. 277-284.  
ISSN: 0730-2312.  
JOURNAL TYPE: Article  
LANGUAGE: English

AB Epidermal growth factor receptor (EGFR), a member of the tyrosine kinase family, has been shown to be involved in growth regulation. In agreement with this, the growth of human prostatic carcinoma



1- $\alpha$ ,25-dihydroxyvitamin D-3 (1,25(OH) $_2$ D-3) regulates the growth and differentiation of several human FT cell lines. Both genomic and non-genomic signalling pathways for 1,25(OH) $_2$ D-3 have been reported, although the mechanism of action in FT cells has not been defined. We now provide data supporting an active role for the nuclear vitamin D receptor (VDR) in mediating the growth-inhibitory effects of 1,25(OH) $_2$ D-3 in these cells. In the VDR-rich cell line A1VA-1, the observed changes in growth by 1,25(OH) $_2$ D-3 are preceded by significant changes in VDR mRNA expression. In contrast, the cell line CA-1, containing few VDRs, fails to show such early changes in VDR gene expression and later changes in growth with 1,25(OH) $_2$ D-3. To assess the role of the VDR more directly, transfection studies were pursued. A1VA-1 cells were stably transfected with an antisense VDR cDNA construct in an attempt to reduce VDR expression. Antisense mRNA expression among clones was associated with: (a) reduced or abolished sensitivity to the effects of 1,25(OH) $_2$ D-3 on growth; (b) decreased numbers of VDRs per cell, as measured by radiolabelled-ligand binding; and (c) a lack of induction of the VDR-regulated enzyme 24-hydroxylase in response to 1,25(OH) $_2$ D-3. From these studies we conclude that the antiproliferative effects of 1,25(OH) $_2$ D-3 require expression of the nuclear VDR in this system.

19 ANSWER 11 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE

14

ACCESSION NUMBER: 1994:256269 BIOSIS  
DOCUMENT NUMBER: BRFV199407269269  
TITLE: Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 24-hydroxyvitamin D-3 24-hydroxylase gene.  
AUTHOR(S): Numa, Yoshiaki; Ito, Kazuo; Kikuchi, Masayuki; Shinkai, Toshimasa; Kato, Shiroaki; Suda, Tetsuo; Yamamoto, Tsamu; Noshino, Mitsuhide; Kato, Yukio  
CORPORATE SOURCE: (1) Graduate Dep. Gene Sci., Fac. Sci., Hiroshima Univ., 1-3-1 Kagamiyama, Higashi-Hiroshima 724 Japan.  
SOURCE: Journal of Biological Chemistry, 1994, Vol. 269, No. 14, pp. 10549-10553.  
ISSN: 0021-9258.  
DOCUMENT TYPE: Article  
LANGUAGE: English

AB The 5'-flanking region of the rat vitamin D-3 24-hydroxylase (F4630cc24) gene was examined and a vitamin D-responsive element (VDRE) responsible for the 1- $\alpha$ ,25-dihydroxyvitamin D-3 (1,25(OH) $_2$ D-3) enhancement was identified. Unidirectional deletion analyses of the 5'-flanking region indicated that the region (-167-122) is involved in vitamin D responsiveness. Further functional analyses showed that the segment (-214-122) conferred the hormone-responsiveness in an orientation-independent manner when it was placed upstream of the heterologous thymidine kinase promoter or the rabbit beta-globin promoter. The segment (-214-122) contained two direct repeat motifs homologous to other VDREs found in the osteocalcin and osteonectin genes. Synthetic oligonucleotide probes stabilizing the putative VDRE were used for functional analyses and gel mobility shift assays. The proximal (-161-122), but not the distal (-214-122) direct repeat activated the transcription in response to 1,25(OH) $_2$ D-3, through the 1- $\alpha$ -25(OH) $_2$ D-3 receptor. Furthermore, the proximal direct repeat formed a complex with the vitamin D receptor and a nuclear accessory factor in FT cells. In addition, K $_2$ Cr $_2$ O $_7$  uptake in the presence of 1,25(OH) $_2$ D-3 was inhibited by the proximal repeat motif. ANSTWAK49944, located at -111 base pairs upstream in the antisense strand binds to a heterodimeric DNA-protein complex of the VDR complexed with 1,25(OH) $_2$ D-3 and the nuclear accessory factor and that it plays a critical role in mediating the vitamin D enhancement of the rat P450c24 gene expression.

14 ANSWER 15 OF 15 MEDLINE MEDLINE JOURNAL ARTICLE INFORMATION

ADDITION NUMBER: 1991:40:11-12  
DOCUMENT NUMBER: 8444:171  
TITLE: REGULATION OF VITAMIN D RECEPTOR mRNA LEVELS IN ALZHEIMER AND HUNTINGTON'S HEMIPARKINSONISM WITH CALBINDIN-28K mRNA LEVELS.  
AUTHOR: GUTHRIE J M R; SHERMAN M L; YOUNG L F R; BEEBE M J; HARTMAN M R; KILPATRICK J P C  
CORPORATE SOURCE: CALCIUM RES. LAB., ST. MICHAEL'S HOSP. ADMIN, 38 JEWELL STREET, TORONTO, ONT. M5S 1A6, CAN.  
SOURCE: MOL BRAIN RES, (1992) 13 (2), 239-251.  
CODEN: MBRER4. ISSN: 0169-328X.  
FILE SEGMENT: BR; 011  
LANGUAGE: English

AB Receptors for vitamin D hormone VDR and the calcium binding protein, calbindin-28k, have been localized in many tissues, including brain. In brain, VDR and calbindin-28k were reported to colocalize in hippocampal CA1 cells. We now show that mRNA pool size for calbindin-28k was reduced, on average, by 30% in Alzheimer hippocampal CA1 cells, as compared to Huntington control (manuscript in preparation). In the present study, in situ hybridization with antisense RNA probes was used to examine VDR expression in paired Alzheimer and Huntington brain tissue. Message levels for VDR were reduced, on average, by 34% and 31%, respectively, in Alzheimer hippocampal CA1 and CA2 pyramidal cells, as compared to Huntington control. However, VDR message levels were not significantly different from control in Alzheimer temporal cortex or cerebellum. There was no correlation between VDR message levels and brain weight, autopsy interval, patient age or the extent of neurofibrillary degeneration. Instead, VDR mRNA pool size in hippocampal CA1 cells correlated significantly with calbindin-28k message levels ( $r = 0.52$ ,  $P < 0.01$ ). Decreased message levels for VDR and calbindin-28k in these cells were due to an increased percentage of cells expressing lower message levels for these proteins. These results show that in Alzheimer hippocampal CA1 cells, VDR mRNA pool size is down-regulated and that this down-regulation may play a role in the reduction of calbindin-28k expression.

14 ANSWER 15 OF 15 MEDLINE MEDLINE JOURNAL ARTICLE  
ADDITION NUMBER: 1991:40:11-12  
DOCUMENT NUMBER: 8444:171  
TITLE: Regulation of VDR mRNA levels with calbindin-28k mRNA levels in Alzheimer's disease and expression in AP-1 transgenic osteoblastic cells.  
AUTHOR: Takeshita Akira; Yasuda Hirohito; Ishida Masami; Ohishi Kuniyasu  
CORPORATE SOURCE: Department of Oral Microbiology, Niigata University School of Dentistry, Saitama, Japan. takeshitadent@nii.ac.jp  
SOURCE: JOURNAL OF ORAL SCIENCE, 12 Mar 94, 1, 1-4.  
Journal Code: 8444:171. ISSN: 0043-4844.  
EXP. COUNTRY: Japan  
DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY NUMBER: 171  
ENTRY DATE: Entered JCN: 1991-12-12  
Last Update JCN: 1994-03-04  
Entered MEDLINE: 1994-03-04

AB A group of studies on Alzheimer's disease (AD) indicated that amyloid precursor protein (APP) is involved in the pathogenesis of AD. In the present study, we showed that calbindin-28k was down-regulated in the hippocampal CA1 cells with APP transgenic mice. In the present study, we showed that calbindin-28k was down-regulated in the hippocampal CA1 cells with APP transgenic mice. In the present study, we showed that calbindin-28k was down-regulated in the hippocampal CA1 cells with APP transgenic mice.

when the cells were incubated with the vitamin for 24 hr before the RA treatment. 22-Oxa-1,25(OH)<sub>2</sub>D<sub>3</sub> DTT, an analog derivative of 1α,25(OH)<sub>2</sub>D<sub>3</sub>, having high affinity for the vitamin D<sub>3</sub> receptor **VDR**, also interfered with the RA-induced inhibition of p21<sup>ras</sup> gene expression in the TNF-α-treated cells. In contrast, this was not the case for 24,25(OH)<sub>2</sub>D<sub>3</sub>. Moreover, we observed that the interference effect was clearly blocked by pretreatment with **VDR antisense** oligonucleotide. 1α,25(OH)<sub>2</sub>D<sub>3</sub> also interfered with RA inhibition of the RA-responsible direct binding activity of AP-1 in the cytosol-treated cells. Furthermore, 1α,25(OH)<sub>2</sub>D<sub>3</sub> actually altered the AP-1-mediated gene expression in a dose-dependent manner. 1α,25(OH)<sub>2</sub>D<sub>3</sub> induced in the cytosol-treated cells. The present study suggests a regulatory interference by 1α,25(OH)<sub>2</sub>D<sub>3</sub> on RA inhibition of TNF-α-induced AP-1 activity in osteoblasts.

19 ANSWER 14 OF 25 MEDLINE JOURNAL ARTICLE  
 ACCESSION NUMBER: 200148218 MEDLINE  
 DOCUMENT NUMBER: 21108446 PubMed ID: 11179731  
 TITLE: 1alpha,25-dihydroxyvitamin D<sub>3</sub> displays divergent growth effects in both normal and malignant cells.  
 AUTHOR: Rashid S F; Mountford J C; Gombart A P; Campbell M J  
 CORPORATE SOURCE: Division of Immunity & Infection, University of Birmingham Medical School, Queen Elizabeth Hospital, Edgbaston, B15 2TT, Birmingham, United Kingdom.  
 SOURCE: STEROIDS, [2001 Mar-May] 66 (3-5): 433-43.  
 Journal code: 04 4836. ISSN: 0039-128X.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200107  
 ENTRY DATE: Entered STN: 20010719  
 Last Updated on STN: 20010719  
 Entered Medline: 20010719

**AB** Induction of growth arrest and differentiation of some cancer cells by 1α,25-dihydroxyvitamin D<sub>3</sub> [1α,25(OH)<sub>2</sub>D<sub>3</sub>], and its potent analogs, is well characterized. However, aggressive cancer cell lines are often either insensitive to the antiproliferative effects of 1α,25(OH)<sub>2</sub>D<sub>3</sub> (2D<sub>3</sub>) or require toxic concentrations to recapitulate them which has, to-date, precluded its use in anticancer therapy. Therefore we are interested in mechanisms by which 1α,25(OH)<sub>2</sub>D<sub>3</sub> signaling has become deregulated in malignant cells in order to identify novel therapeutic targets. We observed previously that 1α,25(OH)<sub>2</sub>D<sub>3</sub> and its metabolites, generated via the C-24 oxidation pathway, drive simultaneous differentiation and hyper-proliferation within the same cell population. Thus we have proposed that metabolism of 1α,25(OH)<sub>2</sub>D<sub>3</sub> via the C-24 oxidation pathway represents a novel-signaling pathway, which integrates proliferation with differentiation. In the current study we examined further the role of this pathway and demonstrated that these effects are not restricted to leukemic cells but are observed also in the normal myeloid progenitors and breast cancer cell lines. Intriguingly, stable transfection of MCF-7 breast cancer cells with **antisense** vitamin D<sub>3</sub> receptor **VDR** reduced antiproliferative sensitivity to 1α,25(OH)<sub>2</sub>D<sub>3</sub> but significantly enhanced growth stimulation, which, in turn, was blocked by inhibiting metabolism of 1α,25(OH)<sub>2</sub>D<sub>3</sub> via C-24 oxidation pathway with ketoprofen. Taken together, these studies indicate that metabolism of 1α,25(OH)<sub>2</sub>D<sub>3</sub> via C-24 oxidation pathway gives rise to ligands with different cellular effects. We propose that this mechanism may allow the C-24 oxidized cell population expansion and cell multiplication during differentiation. In fact cells appear to corrupt this process during malignant transformation, by only responding to the pro-proliferative signals, thereby derailing a signal pathway.

1. ANSWER 1 OF 12 MEDLINE DUPLICATE 1  
 ATTENTION NUMBER: 431626 MEDLINE  
 COMMENT NUMBER: 431626 PubMed ID: 1148427  
 TITLE: The anti-proliferative effects of  $1\alpha,25(OH)_2D_3$  in breast and prostate cancer cells are associated with induction of BRCA1 gene expression.  
 AUTHOR: Campbell M J; Whitart A P; Kwok S H; Park S; Kessler H J  
 CORPORATE SOURCE: Department of Medicine, Division of Medical Sciences, University of Birmingham, Clinical Research Institute, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK.  
 JOURNAL: ANGIOGENE, (2001) Vol 14, Iss 44, P 41-1.  
 JOURNAL cite: 431626. ISSN: 1471-0048.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: Journal; Article; [JOURNAL ARTICLE]  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 1/2001  
 ENTRY DATE: Entered JCR: 1/1/2001  
 Last Update: 1/1/2001  
 Entered Medline: 1/1/2001

AB The anti-proliferative action of the semi-steroid hormone  $1\alpha,25(OH)_2D_3$  extends to some, but not all breast and prostate cancer cell lines. By elucidating the molecular mechanisms mediating the sensitivity of these cells, we can identify critical target genes regulated directly or indirectly by  $1\alpha,25(OH)_2D_3$  and pathways potentially disrupted during transformation. In this study, we demonstrated the induction of expression of BRCA1 mRNA and protein as well as transcriptional activation from the BRCA1-promoter by  $1\alpha,25(OH)_2D_3$  in the sensitive breast cancer cell line MCF-7. This was not observed in the  $1\alpha,25(OH)_2D_3$ -resistant breast cancer cell line MDA-MB-436. The induction of BRCA1 mRNA was blocked by cyclohexamide. This indicated that transcriptional activation was mediated indirectly by the vitamin D receptor (VDR). Inhibition of VDR protein levels by stable transformation of the anti-sense VDR in MCF-7 reduced the sensitivity of MCF-7 to  $1\alpha,25(OH)_2D_3$  by 20-fold. In addition, the induction of BRCA1 protein and transcriptional activation at a BRCA1 promoter-luciferase reporter construct was attenuated in the stable transformant with the greatest reduction of VDR levels. Examination of other breast and prostate cancer cell lines revealed that sensitivity to the anti-proliferative effects of  $1\alpha,25(OH)_2D_3$  was strongly associated with an ability to modulate BRCA1 protein. Furthermore, the expression of the estrogen receptor in these cell lines strongly correlated with their sensitivity to  $1\alpha,25(OH)_2D_3$  and their ability to modulate BRCA1 expression. Taken together, our data support a model whereby the anti-proliferative effects of  $1\alpha,25(OH)_2D_3$  are mediated, in part, by the induction of BRCA1 gene expression via transcriptional activation by factors induced by the VDR and that this pathway is disrupted during the development of prostate and breast cancers.

19 ANSWER 16 OF 23 MEDLINE DUPLICATE 16  
 ATTENTION NUMBER: 431630 MEDLINE  
 COMMENT NUMBER: 431630 PubMed ID: 1148427  
 TITLE: Gene expression, signal transduction and tissue-specific differentiation during mammary epithelial growth.  
 AUTHOR: Alizadeh H Z; Hu C Y; Alizadeh Y; Alizadeh Z; Hu Y; May M; Alizadeh Z; Alizadeh Y; Alizadeh Z; Alizadeh Y  
 CORPORATE SOURCE: Center for Gene Expression, Molecular Biology, University of California, Berkeley, CA 94720-5080, USA.  
 JOURNAL: CRITICAL REVIEWS IN EMBRYOLOGY AND MOLECULAR DEVELOPMENT, (2001) Vol 31, Iss 1, P 1-1.  
 JOURNAL cite: 431630. ISSN: 1044-579X.

PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
 General Review; REVIEW  
 REVIEW, ACADEMIC  
 LANGUAGE: English  
 FILE NUMBER: Primary Number; 1994-11-15  
 ENTRY MONTH: 1994  
 ENTRY DATE: Entered STM: 1994-11-15  
 Last Updated on STM: 1994-11-15  
 Entered Medline: 1994-11-15

AB Bone development provides a paradigm for understanding the roles of the cell- and extracellular matrix (ECM)-mediated mineralization. The intent of this review is to evaluate the sequential timing and critical information prerequisite for tissue-specific biomineralization. Recent investigations suggest that 1,25-dihydroxyvitamin D<sub>3</sub> functions to up-regulate VDR (vitamin D receptor), that in turn could induce structural gene products, including calcium-binding proteins and several ECM proteins (e.g., enamelin, amelogenin, dentine sialoproteins [DSP] and dentine phosphoproteins [DPP]), resulting in dentine and enamel formation. Inhibition of regulatory gene products and/or their receptors likely results in hypoplastic and/or hypomineralized ECM as a direct consequence of down-regulated (1) transcription and/or translation of structural and regulatory genes, (2) posttranslational modifications, (3) and/or decreased calcium transport to the forming dentine and enamel matrices. Advances in serumless in vitro culture methodology; computer-assisted access to nucleic acid sequences for probes to define when, where, and how many specific regulatory and structural gene products are expressed; antisense oligonucleotide tides to inhibit specific translation; and microchip assays to analyze biomineralization will provide additional avenues to investigate tissue-specific biomineralization.

L9 ANSWER 17 OF 23 MEDLINE

ACCESSION NUMBER: 2001130658 MEDLINE  
 DOCUMENT NUMBER: 2124137 Pubmed ID: 11149454  
 TITLE: 1,25-hydroxyvitamin D 3alpha-hydroxylase: structure of the mouse gene, chromosomal assignment, and developmental expression.  
 AUTHOR: Panda D K; Al Kawas S; Seldin M F; Hendy G N; Goltzman D  
 CORPORATE SOURCE: Calcium Research Laboratory, Royal Victoria Hospital, Montreal, Quebec, Canada.  
 SOURCE: JOURNAL OF BONE AND MINERAL RESEARCH, (2001 Jan 16) 16: 46-56.  
 Journal code: JBM 16(1) ISSN: 8894-7431.

PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; JOURNAL ARTICLE  
 LANGUAGE: English  
 FILE NUMBER: Primary Number  
 ENTRY MONTH: 1994  
 ENTRY DATE: Entered STM: 1994-11-15  
 Last Updated on STM: 1994-11-15  
 Entered Medline: 1994-11-15

AB The murine homolog of the 1,25-hydroxyvitamin D<sub>3</sub> 3alpha-hydroxylase gene (3alpha-Hase; Cyp. 27B), which is mutated in humans with vitamin D-dependent rickets type 1 (VDR-1; also known as pseudovitamin D-deficiency rickets [PDDR]), was cloned and characterized. In the human, the rickets gene has two exons, and the exon-intron organization is well conserved. By interspecific database analysis, the Cyp. 27B gene was mapped to 7p11.6 on mouse Chr 7. This is in a region syntenic with human Chr 12q13-13.3, which the human 3alpha-Hase gene was previously mapped. Tissue expression of the 3alpha-Hase was localized to cortical trabeculae and was higher in the adult than in the fetus, consistent with the increased role of this gene in bone

circulating hormone postnatally. Eventually, the  $\alpha$ 1(I)OHase gene, together with the vitamin D receptor **VDR** gene, was expressed in embryonic stem cells, and expression of  $\alpha$ 1(I)OHase in bone and intestine was higher in the fetus than in the adult. These observations suggest that 1,25-dihydroxyvitamin D [ $1,25(OH)_2D_3$ ] plays a role in fetal development. In view of the fact that humans lacking  $\alpha$ 1(I)OHase have apparently normal prenatal development, this may point to functional redundancy in the fetal vitamin D system, which now can be explored further in mouse models in which the  $\alpha$ 1(I)OHase gene has been deleted.

17 ANSWER 17 OF 18 JARVIS COPYRIGHT 2003 ABC

ADDITIONAL NUMBER: 1711-1716 JARVIS

CURRENT NUMBER: 1711-1716

TITLE: Assessing Single Nucleotide Polymorphisms in Genomic DNA by Direct Multiplex Polymerase Chain Reaction Amplification of Oligonucleotide Microarray  
AUTHOR(S): Huber, Martin; Klenke, Axel; Linschoten, Eva; Schneekerman, Christian; Toppert, Thomas H.; Döller, Manfred W.; Schmidt, Wolfgang M.

CORPORATE SOURCE: VEC-GENOMICS Bioscience Research GmbH, Vienna, 1030, Austria

SOURCE: Analytical Biochemistry (2002), 303(1), 28-33

CODEN: ANBCA2; ISSN: 0003-2697

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This study introduces a DNA microarray-based genotyping system for accessing single nucleotide polymorphisms (SNPs) directly from a genomic DNA sample. The described one-step approach combines multiplex amplification and allele-specific solid-phase PCR into an on-chip reaction platform. The multiplex amplification of genomic DNA and the genotyping reaction are both performed directly in the microarray in a single reaction. Oligonucleotides that interrogate single nucleotide positions within multiple polymorphisms of interest are covalently tethered to a glass chip, allowing direct anal. of reaction products by fluorescence scanning. Due to a fourfold SNP detection approach employing simultaneous probing of sense and **antisense** strand information, genotypes can be automatically assigned and validated using a simple computer algorithm. We used the described procedure for parallel genotyping of 10 different polymorphisms in a single reaction and successfully analyzed more than 100 human DNA samples. More than 99% of genotype data were in agreement with data obtained in control expts. with allele-specific oligonucleotide hybridization and capillary sequencing. Our results suggest that this approach might constitute a powerful tool for the anal. of genetic variation.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REF SUMMARY

18 ANSWER 18 OF 18 JARVIS COPYRIGHT 2003 ABC

ADDITIONAL NUMBER: 1711-1716 JARVIS

CURRENT NUMBER: 1711-1716

TITLE: Effect of **VDR** on proliferation and activity of 1,25-dihydroxyvitamin D in human embryonic stem cells  
AUTHOR(S): Chen, Yuxia; Liu, Yaliang; Chen, Liannan

CORPORATE SOURCE: Department of Pathophysiology, Second Military Medical University, Shanghai, 20043, P.R. China

SOURCE: Chinese Medical Journal (2002), 77(1), 40-44  
CODEN: CMJEDH; ISSN: 1001-9071

PUBLISHER: China Press

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

AB This study explored the vitamin D receptor **VDR** in embryonic 1,25-dihydroxyvitamin D [ $1,25(OH)_2D_3$ ] and its novel analogs in human

osteosarcoma cell line HOS- $\alpha$ 13 was stably transfected. VDR mRNA and protein expression in HOS- $\alpha$ 13 cells were detected by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochem., resp., and its function was detected by transient transfection of a reporter gene (p30-tk-CAT) by VDR. The effect of 1,25(OH) $_2$ D $_3$  on proliferation of HOS- $\alpha$ 13 cells and induction of p30 mRNA, and of the VDR target genes, after blockade of VDR in the cells was tested by using cell VDRase stably expressing VDR antisense mRNA. The VDR as a hormone-dependent transcriptional factor was expressed in HOS- $\alpha$ 13 cells. The inhibitory effects of 1,25(OH) $_2$ D $_3$  on its analogs on proliferation of HOS- $\alpha$ 13 cells and induction of p30 gene expression were decreased after blockade of VDR in the cells. The results showed that the effect of 1,25(OH) $_2$ D $_3$  on the proliferation of human osteosarcoma cell line HOS- $\alpha$ 13 was mediated by the action of VDR.

19 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:00046  
 DOCUMENT NUMBER: 133:00046  
 TITLE: Establishing a human osteosarcoma cell line of stably-transfected vitamin D receptor antisense cDNA  
 AUTHOR(S): Chen, Yuxia; Liu, Yujian; Song, Liangnian  
 CORPORATE SOURCE: Department of Pathophysiology, Department of Basic Medicine, Second Military Medical University, Shanghai, 200433, Peop. Rep. China  
 SOURCE: Dier Junyi Daxue Xuebao (2003), 22(3), 242-244  
 CODEN: DEXUEL; ISSN: 0256-879X  
 PUBLISHER: Dier Junyi Daxue Xuebao Bianjibu  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Chinese

AB A human osteosarcoma cell line stably-transfected with human vitamin D receptor (VDR) antisense cDNA was established. The eukaryotic expression vector harboring VDR antisense cDNA was constructed, and transfected into the human osteosarcoma cell line HOS- $\alpha$ 13 by lipofectamine method. The stable transfectants were screened by PCR and the expression of endogenous VDR was further detected at protein level by immunohistochem. anal. The transcriptional activity mediated by VDR in the VDRase cells was detected at reporter gene level by transient transfection method. Six subclones (VDRase1-6) were isolated, and the level of endogenous VDR expression in the VDRase cells decreased significantly compared with that in the control cells. The transcriptional activity of the reporter gene CAT in the control cells increased by 3.5-fold when treated with  $1 \times 10^{-6}$  M 1,25(OH) $_2$ D $_3$  for 24 h, but the transcription of CAT in the VDRase cells could not be induced by 1,25(OH) $_2$ D $_3$ . A cell line stably expressing VDR antisense cDNA is established for the further study of the mol. mechanisms of 1,25(OH) $_2$ D $_3$  action and its analogs on proliferation and differentiation of the human osteosarcoma cell line.

19 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:00046  
 DOCUMENT NUMBER: 133:00046  
 TITLE: The use of epithelial and the use of cancer cell lines to study the mechanism of action of the anti-cancer drug, 1,25(OH) $_2$ D $_3$   
 AUTHOR(S): Chen, Yuxia; Liu, Yujian; Song, Liangnian  
 CORPORATE SOURCE: Department of Pathophysiology, Department of Basic Medicine, Second Military Medical University, Shanghai, 200433, Peop. Rep. China  
 SOURCE: Dier Junyi Daxue Xuebao (2003), 22(3), 242-244  
 CODEN: DEXUEL; ISSN: 0256-879X  
 PUBLISHER: Dier Junyi Daxue Xuebao Bianjibu  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Chinese

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5,144,141	AL	1992-11-11	US 1991-010141	1991-01-11
IN: CA, CH, DE, DK, ES, FR, GB, GR, IE, IL, IN, JP, KR, NL, PT, SE, SI, SK, TR, US, ZA EP 1,014,141 AL 1,014,141 AT 1,014,141				
FI 1,014,141 AL 1,014,141 AT 1,014,141 FI 1,014,141 AL 1,014,141 AT 1,014,141				

PRIORITY APPLIC. INFO.:

US 1991-010141 A 1991-01-11  
 WO 91/01971 W 1991-01-11

AB This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biol. sample from an animal (e.g., a human patient); (ii) detecting the level of CYP24 within the biol. sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biol. sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.

REFERENCES CITED: THERE ARE NO REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFERENCE

IP ANSWER 22 OF 2: TABLES COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:339116 CAPLUS  
 DOCUMENT NUMBER: 129:12943  
 TITLE: Method of treating Kaposi's sarcoma by vitamin-D<sub>3</sub> receptor agonists  
 INVENTOR(S): Gill, Parkash S.  
 PATENT ASSIGNER(S): Gill, Parkash S., USA  
 SOURCE: EPI Int. Appl., 34 pp.  
 CODEN: EPIKXD  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5,144,141	AL	1992-11-11	US 1991-010141	1991-01-11
IN: AL, AM, AR, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CO, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HU, IL, IN, IS, JP, KE, KG, KH, KP, KR, KZ, LA, LB, LG, LI, LU, LV, MD, MG, MK, MN, MX, MY, NZ, OM, OS, PT, RO, RU, SE, SG, SI, SK, SL, TR, TT, UA, UG, US, UZ, VC, VE, YU, ZA, ZM, ZW, AU, BR, CA, CH, CN, CO, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HU, IL, IN, IS, JP, KE, KG, KH, KP, KR, KZ, LA, LB, LG, LI, LU, LV, MD, MG, MK, MN, MX, MY, NZ, OM, OS, PT, RO, RU, SE, SG, SI, SK, SL, TR, TT, UA, UG, US, UZ, VC, VE, YU, ZA, ZM, ZW				

AT 1,014,141 AL 1,014,141 AT 1,014,141

PRIORITY APPLIC. INFO.:

US 1991-010141 A 1991-01-11  
 WO 91/01971 W 1991-01-11

AB A novel and effective method for treating Kaposi's sarcoma (KS) in patients, by administration of an effective amt. of vitamin-D<sub>3</sub> receptor agonists. VDR agonists are capable of inhibiting the growth of KS cells in culture by suppressing the levels of growth promoting growth factors, IL-1 and IL-6, in KS cells. The VDR agonists may be administered to KS patients typically, orally, in a palatable. Subsequent improvement in KS lesions is expected by topical treatment with a VDR agonist specifically designed for this purpose. Greater efficacy in lessening KS lesions may be achieved



by combination therapy with VDR agonists and IL-1, IL-6, and IL-12 inhibitors. Pharmacological, animal, and the VDR agonists are also claimed.

12 ANSWER 12 OF 15 CANCERLIT

ACCESSION NUMBER: 976 4-18 CANCERLIT

DOCUMENT NUMBER: 97604818

TITLE: Suppression of the 25-hydroxyvitamin D3 24-hydroxylase gene expression by the human TR4 orphan receptor, a member of steroid receptor superfamily. Meeting abstract.

AUTHOR: Lee Y F; Yoon W J; Burdick J L; Chang J

ORIGINATOR: Emory Univ, Emory Cancer Center, 1365 Clifton Road, NE, Atlanta, GA 30307

ADDRESS: Emory Univ, Emory Cancer Center, 1365 Clifton Road, NE, Atlanta, GA 30307

ENTRY DATE: 1997-11-18

DOCUMENT TYPE: MEETING ABSTRACT

LANGUAGE: English

FILE SEGMENT: Institute for Cell and Developmental Biology

ENTRY MONTH: 1997-11

ENTRY DATE: Entered STN: 19980417

Last Updated on STN: 19980417

AB Human TR4 orphan was demonstrated to repress the retinoid signal pathway by occupancy of the response element for RAR and RXR with higher affinity compared with the RAR/RXR heterodimer. Here we demonstrate that human TR4 orphan receptor specifically binds to AGGTCA direct repeats spaced by 4 nucleotides (DR4), a response element for vitamin D receptor (VDR). In addition, in transient transfection, we found TR4 orphan receptor suppresses rat 25-hydroxyvitamin D3 24-hydroxylase gene promoter activity which contains native response element for vitamin D receptor. This suppression is dose and VDR response element dependent. The antisense staining of 10.5-day mouse embryos showed that TR4 orphan receptor can co-localize with VDR in mouse kidney and intestine, which further supported the idea that TR4 orphan receptor could be involved in the regulation of vitamin D system, a system involved in the proliferation and differentiation of tumor cells.

[illegible]

15 This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biol. sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biol. sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biol. sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.

11. ANSWER 1 OF 4 BIOSIS COPYRIGHT © 1993 BIOLOGICAL ABSTRACTS INC.  
 ACCESSION NUMBER: 1495:56194 BIOSIS  
 DOCUMENT NUMBER: PREVIOUS: 51494  
 TITLE: **Ribozyme-mediated degradation of human vitamin D receptor mRNA**  
 activity in cell culture.  
 AUTHOR(S): Simbart, A. F.; Heber, D.; Koeffler, H. P.  
 CORPORATE SOURCE: Div. Hematol.-Oncol., Cedars-Sinai Med. Center, UCLA J. Med., Div. Nutrition, Los Angeles, CA USA  
 SOURCE: Blood, 1994, Vol. 84, No. 11, 3711-1, pp. 100A.  
 Meeting Info: Abstracts Submitted to the 4th Annual Meeting of the American Society of Hematology, Nashville, Tennessee, USA December 1-5, 1993  
 ISSN: 0006-4728  
 DOCUMENT TYPE: Conference  
 LANGUAGE: English

11. ANSWER 1 OF 4 BIOSIS COPYRIGHT © 1993 BIOSIS  
 ACCESSION NUMBER: 92:146111 PLUS  
 DOCUMENT NUMBER: 197:54712  
 TITLE: **Construction of lentiviral vectors for inducible high level controlled expression of transcribed genes in mammalian cells and therapeutical uses**  
 INVENTOR(S): Evans, Ronald M.; Saen, Enrique; Verma, Inder K.  
 PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, USA  
 SOURCE: PCT Int. Appl., 41 pp.  
 CODEN: PEXMD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 92/00004	A1	1992/01/01	WO 92/00004	1992/01/01
WI: AE, AG, AL, AM, AT, AU, BA, BB, BF, BG, BY, BE, CA, CH, CN, CO, CR, CU, DE, DK, DM, DO, DR, ES, FI, FR, GB, GR, GU, HK, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LC, LI, LU, LV, MA, MD, ME, MG, MN, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VE, VN, YU, ZA, ZM, ZW, AM, AO, BY, KB, KG, MD, RU, TJ, TM				
RW: BR, BS, CH, DE, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VE, VN, YU, ZA, ZM, ZW, AM, AO, BY, KB, KG, MD, RU, TJ, TM				

PRIORITY APPL. INFO.: US 1991-0-03077 P 1991/04/01

AB The present invention provides inducible gene transfer systems and gene transfer vectors of lentivirus for the safe and effective transfer and expression of genes in mammalian cells, and for a very high level of control of expression of the transferred genes. The inducible gene transfer systems of the present invention may be lentiviral vectors comprising a self-inactivating 3' LTR, a modulator-responsive promoter, a nuclear import signal, a promoter operatively associated with a modulator and one or more inducer-responsive elements, an RNA stabilizing element, and a self-inactivating 5' LTR. Thus, the present invention provides a safe and effective gene transfer system for the transfer and expression of genes in mammalian cells. The present invention also provides a safe and effective gene transfer system for the transfer and expression of genes in mammalian cells with the gene transfer systems of the present invention, and a safe and effective gene transfer system.

11. ANSWER 2 OF 4 BIOSIS COPYRIGHT © 1993 BIOSIS  
 ACCESSION NUMBER: 92:146111 PLUS  
 DOCUMENT NUMBER: 197:54712  
 TITLE: **Construction of lentiviral vectors for inducible high level controlled expression of transcribed genes in mammalian cells and therapeutical uses**

presence or progression of a pre-disposition to cancer  
 Albrecht, Linda A.; Bineel, Daniel; Collins, Tonia;  
 Day, Joe W.; Yatta, Rakesh  
 PATENT ASSIGNMENT: Repare, Inc. - University of California, USA  
 SOURCE: INT. IN. Appl., 1999  
 CLASS: E16H01  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY APP. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000/01041	A1	20000104	WO 99/05041	19990504
K: CA, JP				
FX: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, NL, NO, SE				
EP 1268880	A1	20001113	EP 2000-016149	20000106
E: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, NO, SE, NO, IT, IE, FI, CY				

PRIORITY APPLIC. INFO.:  
 US 1999-288292 A 19990472  
 WO 2000-05041 W 20000104

AB This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biol. sample from an animal (e.g., a human patient); (ii) detecting the level of CYP24 within the biol. sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biol. sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

116 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 AIS

ACCESSION NUMBER: 2000:161479 CAPLUS  
 DOCUMENT NUMBER: 132:204016  
 TITLE: Adenoviral vectors and inducible expression system for gene expression and therapy  
 INVENTOR(S): Mehtali, Nadia; Sorn-pue, Tania  
 PATENT ASSIGNEE(S): Transgene S.A., FR.  
 SOURCE: INT. IN. Appl., 1999  
 CLASS: E16H01  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY APP. COUNT: 1  
 PATENT INFO COUNT: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000/01041	A1	20000104	WO 1999-05041	19990504
WO 2000/01041	A1	20000104		
K: AT, CA, JP, US				
FX: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, NL, NO, SE				
EP 1268880	A1	20001113	EP 1999-016149	19990106
CA 2341000	A1	20000104	CA 1999-016149	19990106
AT 20000104	A1	20000104	AT 1999-016149	19990106
EP 1268880	A1	20001113	EP 1999-016149	19990106
E: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, NO, SE, NO, IT, IE, FI				
WO 2000/01041	A1	20000104	WO 1999-05041	19990504

AB The invention concerns an inducible expression system using nucleotide sequences coding for a transcriptional activator of eukaryotic or viral origin and a recombinant adenoviral vector comprising a gene of interest placed under the control of a promoter inducible in trans by said transcriptional activator. The invention also concerns a recombinant adenoviral vector bearing a first expression cassette coding for a transcriptional activator and a second cassette bearing a gene of interest placed under the control of a promoter inducible in trans by said transcriptional activator. The invention further concerns an adenoviral particle, its preparation, a eukaryotic cell and a pharmaceutical composition comprising such a vector or expression system as well as their use for therapeutic or prophylactic purposes. Thus, an adenoviral vector coding genes for interleukin-2 receptor (IL2R) and for a tumor suppressor factor IX regulated by an enhancer was prepared. Factor IX gene expression was induced in vitro and in vivo by dexamethasone.

[illegible][illegible]

Figure 1. (a) Schematic diagram of the experimental setup. (b) Photograph of the experimental setup. (c) Photograph of the experimental setup. (d) Photograph of the experimental setup.

[illegible]

$\rho_{\text{eff}} = \frac{\rho}{1 + \beta} = \frac{\rho}{1 + \frac{1}{\gamma}}$

ATTACHED : Terrence, Christopher M.; Hrusaker, Paul A.;  
Tarnoff, John M.; Sullivan, Michael A.; Mann, Perry  
L.; Hrusaker, Mark B.

Следствие:  $\lim_{n \rightarrow \infty} \frac{1}{n} \sum_{k=1}^n \frac{1}{k} = 0$ .

$$f_{\text{eff}} = \frac{f_{\text{eff}}^{\text{max}}}{1 + \exp\left(\frac{1}{\alpha} \ln\left(\frac{f_{\text{eff}}^{\text{max}}}{f_{\text{eff}}}\right)\right)} \quad (1)$$
[illegible]

THE UNIVERSITY OF CHICAGO PRESS

[illegible]

The gene for rat bone gla protein (BSP) was isolated and 1.6 kb fragments (bp), including 110 bp of 5' flanking DNA, were placed up-stream of the human CMV reporter gene. After transient transfection into the osteoblast-like rat osteosarcoma cell line ROS 17/2.8, the BSP promoter demonstrated a low level of basal activity that was increased approx. 10-fold by the admin. of  $10^{-8}$  M 1,25-dihydroxyvitamin D<sub>3</sub> [1,25-(OH)<sub>2</sub>D<sub>3</sub>]. A single 250-bp fragment (-110 to -50) was sufficient to confer hormone insensitivity upon both heterologous and homologous promoters. Deletion studies, complemented by evaluation with synthetic oligomers, enabled localization of the 1,25-(OH)<sub>2</sub>D<sub>3</sub> response element to within 14 bp (-64 to -50), with an element with an imperfect direct repeat (ATTGCA, CACCA) and homologous to other steroid-responsive elements. Gel retardation assays demonstrated that partially purified chick intestinal 1,25-(OH)<sub>2</sub>D<sub>3</sub> receptor bound specifically and with high affinity to a DNA fragment containing the putative 1,25-(OH)<sub>2</sub>D<sub>3</sub> response element, and this binding was perturbed by monoclonal antibodies to the 1,25-(OH)<sub>2</sub>D<sub>3</sub> receptor. Surprisingly, the 250-bp fragment, when linked in an **antisense** orientation with respect to the BSP promoter, blocked basal and hormone-dependent gene expression. However, a 246-bp fragment 5' to the 250-bp element (-110 to -50) restored 2-fold insensitivity when linked to the first fragment in the same orientation, suggesting the cooperativity between at least two elements to achieve the hormonal regulation observed in this gene.